Biosimilars

The findings of an online, cross-sectional survey indicate oncologists were less likely to prescribe biosimilars if their practice could lose money and control of the drug, despite clinical safety and efficacy between the biosimilar and originator. Read More ›

Real-world data indicate treatment adherence was highest among patients who had prior infliximab exposure but no prior infliximab biosimilar use. Read More ›

Real-world data from the ONWARD study indicate that patients with inflammatory bowel syndrome (IBS) who initiate or switch to infliximab-dyyb achieve significant improvement of clinical outcomes and quality of life. Read More ›

Data from a large, nationwide, observational cohort study demonstrate that switching from reference infliximab to biosimilar infliximab-abda in patients with inflammatory bowel disease was safe and efficacious compared with continuing reference infliximab. Read More ›

Confirmatory phase 3 clinical trial results demonstrated equivalence between MYL-1402O and bevacizumab in terms of efficacy, safety, and immunogenicity in the first-line treatment of patients with stage IV metastatic, nonsquamous non–small-cell lung cancer (NSCLC). Read More ›

The results of a phase 3 trial demonstrated the clinical equivalence of MB02 with bevacizumab reference product in terms of efficacy, safety, and immunogenicity in patients with stage IIIB/IV nonsquamous non–small-cell lung cancer (NSCLC). Read More ›

Phase 3 trial results demonstrate equivalence between the bevacizumab biosimilar FKB238 and bevacizumab reference in terms of efficacy and safety in patients with advanced/recurrent nonsquamous non–small-cell lung cancer (NSCLC). Read More ›

The results of a phase 1 pharmacokinetic and safety equivalence study demonstrated equivalence between HD204 and both bevacizumab-EU and bevacizumab-US in healthy males. Read More ›

Population-based study results support the use of the neoadjuvant chemotherapy + pertuzumab + trastuzumab biosimilar SB3 treatment regimen in the real-world setting, with responses comparable with those achieved in clinical trials. Read More ›

Real-world utilization data indicate that treatment outcomes with infliximab biosimilars were similar to those with reference infliximab in patients with rheumatoid arthritis. Read More ›